SLU-PP-332 and Tamoxifen Interaction

Avoid
Mechanism-based 53% confidence

SLU-PP-332 and Tamoxifen have a potentially harmful interaction with 53% confidence. Both SLU-PP-332 and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

SLU-PP-332

Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator

Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.

Half-life: Under investigation (no human PK data) Typical dose: NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP) metabolic, longevity
ampk hepatotoxicinsulin disrupting
View full profile

Tamoxifen

Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment

Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling.

Half-life: ~5-7 days Typical dose: 20-40mg oral daily pct
cyp3a4estrogen receptor anticoagulantcarcinogenic riskhepatotoxicpct agent
View full profile

Combined Organ Load

Pancreas
low
Gonads
low
Pituitary
low

Shared Safety Flags

2x 2 hepatotoxic compounds (SLU-PP-332, Tamoxifen). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.

Frequently Asked Questions

Can I take SLU-PP-332 with Tamoxifen?

Combining SLU-PP-332 with Tamoxifen is not recommended. Both SLU-PP-332 and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is SLU-PP-332 and Tamoxifen safe together?

This combination carries significant risk. Both SLU-PP-332 and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between SLU-PP-332 and Tamoxifen?

Both SLU-PP-332 and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 53% confidence and is inferred from pharmacological mechanism analysis.

How should I time SLU-PP-332 and Tamoxifen?

SLU-PP-332 has a half-life of Under investigation (no human PK data) and Tamoxifen has a half-life of ~5-7 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: SLU-PP-332 vs Tamoxifen

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.